Rapid Medical Diagnostics specializes in the development and commercialization of urine-based diagnostic test strips for Bilharzia (Schistosomiasis), specifically targeting the detection of active infections caused by the Schistosoma parasites. The primary technology employed is the urine-CCA (Circulating Cathodic Antigen) cassette test, which qualitatively detects the presence of CCA in urine. This test is notable for its ability to identify active infections, including those caused by S. mansoni and S. haematobium, by demonstrating the presence of antigens secreted by adult worms. Unlike traditional serum antibody tests, which may not reliably differentiate between active and inactive infections, the urine-CCA test provides a more accurate assessment of current infections, making it a valuable tool for both clinical diagnosis and epidemiological studies.

The development of the urine-CCA test is rooted in extensive research conducted at the Department of Parasitology at LUMC in the Netherlands, where advancements in monoclonal antibody technology have led to the creation of highly sensitive and specific lateral flow assays. This technology allows for rapid testing in field conditions without the need for laboratory facilities, making it particularly useful in remote areas where traditional diagnostic methods may be impractical. The urine-CCA test is designed to be user-friendly and efficient, providing healthcare professionals with a quick presumptive diagnosis of Bilharzia, which can be crucial for timely treatment and management of the disease.

New Zealand

Rapid Medical Diagnostics is proud to be part of the commercialization and rollout of urine based Bilharzia (Schistosoma) diagnostic test strips. Production of the rapid test strips is the final result of years of research and extremely hard work by several people and institutions.

Rapid Medical Diagnostics

Company Details